Literature DB >> 21741307

Polypharmacy in elderly patients with cancer: clinical implications and management.

Judith Lees1, Alexandre Chan.   

Abstract

More and more elderly people with cancer are treated in oncology clinics worldwide every year, many of whom have comorbid disorders treated with one or more drugs. Moreover, these patients might also take self-prescribed over-the-counter drugs or complementary and alternative medicines, which they might not tell their doctor about. Initiation of chemotherapy with one or more cytotoxic or targeted agents and drugs for treatment of cancer symptoms or toxic effects related to treatment can result in polypharmacy. We examine the clinical implications of polypharmacy. Challenges for the medical teams who treat elderly patients with cancer include identification of what drugs are actually being taken by the patient, avoidance or management of any adverse effects or drug interactions, and reassessing the patient's overall treatment. We address these issues and propose practical recommendations for management of treatment for elderly patients with cancer.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21741307     DOI: 10.1016/S1470-2045(11)70040-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  60 in total

1.  Senior adult oncology.

Authors:  Arti Hurria; Ilene S Browner; Harvey Jay Cohen; Crystal S Denlinger; Mollie deShazo; Martine Extermann; Apar Kishor P Ganti; Jimmie C Holland; Holly M Holmes; Mohana B Karlekar; Nancy L Keating; June McKoy; Bruno C Medeiros; Ewa Mrozek; Tracey O'Connor; Stephen H Petersdorf; Hope S Rugo; Rebecca A Silliman; William P Tew; Louise C Walter; Alva B Weir; Tanya Wildes
Journal:  J Natl Compr Canc Netw       Date:  2012-02       Impact factor: 11.908

2.  Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial.

Authors:  Kevin T Liou; James C Root; Sheila N Garland; Jamie Green; Yuelin Li; Q Susan Li; Philip W Kantoff; Tim A Ahles; Jun J Mao
Journal:  Cancer       Date:  2020-04-22       Impact factor: 6.860

3.  Potential drug interactions in patients with a history of cancer.

Authors:  L Chen; W Y Cheung
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

4.  Deprescribing in Advanced Illness: Aligning Patient, Clinician, and Health Plan Goals.

Authors:  Natasha Parekh; Yael Schenker; Chester B Good; Lynn Neilson; William H Shrank
Journal:  J Gen Intern Med       Date:  2019-02-04       Impact factor: 5.128

5.  Cancer survivors: a booming population.

Authors:  Carla Parry; Erin E Kent; Angela B Mariotto; Catherine M Alfano; Julia H Rowland
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10       Impact factor: 4.254

Review 6.  Polypharmacy and potentially inappropriate medication use in geriatric oncology.

Authors:  Manvi Sharma; Kah Poh Loh; Ginah Nightingale; Supriya G Mohile; Holly M Holmes
Journal:  J Geriatr Oncol       Date:  2016-08-03       Impact factor: 3.599

7.  Prevalence and factors associated with polypharmacy in older people with cancer.

Authors:  Justin P Turner; Sepehr Shakib; Nimit Singhal; Jonathon Hogan-Doran; Robert Prowse; Sally Johns; J Simon Bell
Journal:  Support Care Cancer       Date:  2014-03-02       Impact factor: 3.603

8.  Geriatric assessment-identified deficits in older cancer patients with normal performance status.

Authors:  Trevor A Jolly; Allison M Deal; Kirsten A Nyrop; Grant R Williams; Mackenzi Pergolotti; William A Wood; Shani M Alston; Brittaney-Belle E Gordon; Samara A Dixon; Susan G Moore; W Chris Taylor; Michael Messino; Hyman B Muss
Journal:  Oncologist       Date:  2015-03-12

9.  Patients with advanced lung cancer: is there scope to discontinue inappropriate medication?

Authors:  Adam Todd; Steve Williamson; Andy Husband; Wasim Baqir; Mairead Mahony
Journal:  Int J Clin Pharm       Date:  2012-12-11

10.  A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma.

Authors:  Steven I Park; Natalie S Grover; Oludamilola Olajide; Adam S Asch; James G Wall; Kristy L Richards; Anna L Sobol; Allison M Deal; Anastasia Ivanova; Matthew C Foster; Hyman B Muss; Thomas C Shea
Journal:  Br J Haematol       Date:  2016-07-22       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.